Table 1.
Demographics and clinical characteristics
| Total number of patients with MS | 185 |
| Self-filled survey, N (%) | 126 (68.1) |
| Phone survey, N (%) | 59 (31.9) |
| Age, years (mean ± SD) | 43.4 ± 10.6 |
| Female sex, N (%) | 134 (72.4) |
| Type of multiple sclerosis, N (%) | |
| Relapsing-remitting | 167 (90.3) |
| Secondary progressive | 7 (3.8) |
| Primary progressive | 7 (3.8) |
| MS/MOGAD overlap | 4 (2.2) |
| Disease duration, years (mean ± SD) | 10.65 ± 7.46 |
| Currently smoking, N (%) | 28 (15.1) |
| Influenza vaccination 2020, N (%) | 97 (52.4) |
| Pneumococcal vaccination 2020, N (%) | 4 (2.2) |
| No prior DMT, N (%a) | 50 (29.4) |
| DMT immediately prior to ocrelizumab, N (%a), [median washout, days] | 117 |
| Any interferon beta | 4 (3.4) |
| Glatiramer acetate | 5 (4.3) |
| Dimethyl fumarate | 7 (6.0), [23.5] |
| Fingolimod | 34 (29.0), [41.0] |
| Natalizumab | 52 (44.0), [42.5] |
| Alemtuzumab | 2 (1.7), [742.5] |
| Rituximab | 11 (9.4), [189] |
| Other | 2 (1.7) |
| Median EDSS score, (1st, 3rd quartiles) | 2.0 (1, 4) |
| Ocrelizumab doses, (mean ± SD) | 4.6 ± 1.3 |
| Mean study period interval, months, (mean ± SD) | 6.7 ± 1.5 |
| Median time from prior infusion to lymphocyte, immunoglobulin levels, months, (1st, 3rd quartiles) | 5.8 (5.4, 6.0) |
| Total patient-years of exposure | 103.9 |
| IgG, g/L, mean ± SD, (N) | 9.54 ± 2.40 (131) |
| IgG < LLNb, N (%) | 3 (2.3) |
| IgA, g/L, mean ± SD, (N) | 1.80 ± 0.92 (98) |
| IgA < LLNb, N (%) | 3 (3.1) |
| IgM, g/L, mean ± SD, (N) | 0.70 ± 0.48 (107) |
| IgM < LLNb, N (%) | 10 (9.3) |
| Lymphocyte count × 109/L, mean ± SD, (N) | 1.67 ± 0.70 (168) |
| Neutrophil count × 109/L, mean ± SD, (N) | 4.57 ± 1.92 (165) |
| CD4+ count × 109/L, mean ± SD, (N)c | 0.93 ± 0.51 (85) |
| CD8+ count × 109/L, mean ± SD, (N)c | 0.40 ± 0.27 (85) |
| CD19+ count × 109/L, mean ± SD, (N)c | 0.02 ± 0.06 (86) |
DMT disease-modifying therapy, EDSS Expanded Disability Status Scale, ESM electronic supplementary material, LLN lower limit of normal, MOGAD myelin-oligodendrocyte antibody disorders, MS multiple sclerosis, SD standard deviation
aPercentage of patients with available data
bIncludes patients who had lymphocyte subsets at extended intervals
cPlease see ESM for LLN reference ranges